Vicore reported a Q3/2019 net loss of SEK22.9m, below our SEK26.4m estimate, due largely to lower R&D costs (SEK13.2m vs. GPSLe SEK15.9m) and other external expenses (SEK4.0m vs. GPSLe SEK4.9m). Cash and cash equivalents stood at SEK172m at the end of September, allowing the company to fund operations into 2021E on our estimates. More importantly, the company confirmed that all major pipeline programmes are on track. Lead asset VP01 (C21) is due to enter two Phase IIa trials in idiopathic
08 Nov 2019
All pipeline programmes on track at Q3 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
All pipeline programmes on track at Q3 results
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
08 Nov 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Vicore reported a Q3/2019 net loss of SEK22.9m, below our SEK26.4m estimate, due largely to lower R&D costs (SEK13.2m vs. GPSLe SEK15.9m) and other external expenses (SEK4.0m vs. GPSLe SEK4.9m). Cash and cash equivalents stood at SEK172m at the end of September, allowing the company to fund operations into 2021E on our estimates. More importantly, the company confirmed that all major pipeline programmes are on track. Lead asset VP01 (C21) is due to enter two Phase IIa trials in idiopathic